Published in Women's Health Weekly, May 22nd, 2006
According to recent research from the United States, "We are conducting clinical vaccine trials with the HER2/neu peptide, E75, in patients with breast cancer. The purpose of this study was to demonstrate clonal expansion of E75-specific CD8+ T cells and to identify intra- and inter-antigenic epitope spreading. Pre-and post-vaccination peripheral blood leukocyte samples (24 node-positive [NP] and 20 node-negative [NN]) from 44 vaccinated patients were analyzed."
"HLA-A2:Ig dimer molecules were loaded with the HER2...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.